Use of zolpidem in the treatment of short-term insomnia – case report Case report

Article Sidebar

Requires Subscription PDF (Język Polski)


Published: Dec 31, 2017
DOI: https://doi.org/10.24292/01.MF.0417.5
Keywords:
sleep disorders, short-term insomnia, stress, treatment

Main Article Content

Halina Sienkiewicz-Jarosz
I Klinika Neurologiczna, Instytut Psychiatrii i Neurologii w Warszawie

Abstract

Sleep disturbances, especially insomnia, affect a large part of adult population. In terms of etiology, insomnia can be divided into primary or secondary, and in terms of duration of sleep problems, as transient (lasting less than one week), acute insomnia with duration of sleep disturbances shorter than one month and chronic exceeding one month. Causes of short-term insomnia are usually acute conditions associated with pain (injury), lifestyle changes or stressful situations. Diagnostics of insomnia usually concentrates on medical history. Treatment involves cognitive-behavioral therapy and pharmacotherapy. The first-line drugs in the treatment of acute insomnia are zolpidem, zopiclone and zaleplon. This article presents a case study of short-term insomnia and methods of its diagnosis and treatment.

Article Details

How to Cite
Sienkiewicz-Jarosz, H. (2017). Use of zolpidem in the treatment of short-term insomnia – case report. Medycyna Faktow (J EBM), 10(4(37), 331-334. https://doi.org/10.24292/01.MF.0417.5
Issue
Vol 10 No 4(37) (2017)
Section
Articles

Copyright © by Medical Education. All rights reserved.

References

1. Léger D., Poursain B., Neubauer D. et al.: An international survey of sleeping problems in the general population. Curr. Med. Res. Opin. 2008; 24(1): 307-317.
2. Ohayon M.M., Reynolds C.F. 3rd: Epidemiological and clinical relevance of insomnia diagnosis algorithms according to the DSM-IV and the International Classification of Sleep Disorders (ICSD). Sleep Med. 2009; 10(9): 952-960.
3. Wichniak A.: Zaburzenia snu. W: Jarema M., Rabe-Jabłońska J.: Psychiatria. Podręcznik dla studentów medycyny. Wydawnictwo Lekarskie PZWL, Warszawa 2011.
4. Wichniak A. Bezsenność. Medycyna Praktyczna [online].
5. DSM-V, 2013.
6. Wichniak A.: Standardy leczenia farmakologicznego wybranych zaburzeń snu. W: Jarema M. (red.): Standardy leczenia farmakologicznego niektórych zaburzeń psychicznych. Via Medica, Gdańsk 2015.
7. Szelenberger W.: Standardy leczenia bezsenności Polskiego Towarzystwa Badań nad Snem. Sen 2006; 6: A1-A10.
8. Ramar K., Olson E.: Management of common sleep disorders. American Family Physician 2013; 88(4): 231-238.
9. Lande R.G., Gragnani C.: Nonpharmacologic approaches to the management of insomnia. J. Am. Osteopath. Assoc. 2010; 110(12): 695-701.
10. Matheson E., Hainer B.L.: Insomnia: Pharmacologic Therapy. Am. Fam. Physician. 2017; 96(1): 29-35.
11. Becker P.M., Somiah M.: Non-benzodiazepine receptor agonists for insomnia. Sleep Med. Clin. 2015; 10: 57-76.
12. MacFarlane J., Morin C.M., Montplaisir J.: Hypnotics in insomnia: the experience of zolpidem. Clin. Ther. 2014; 36: 1676-1701.
13. NICE. Guidance on the use of zaleplon, zolpidem and zopiclone for the short-term management of insomnia. April 2004 [online].
14. Krystal A.D., Erman M., Zammit G.K. et al.: Long-term efficacy and safety of zolpidem extended-release 12.5 mg, administered 3 to 7 nights per week for 24 weeks, in patients with chronic primary insomnia: a 6-month, randomized, double-blind, placebo-controlled, parallel-group, multicenter study. Sleep 2008; 31(1): 79-90.